![Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine](https://www.pdfsearch.io/img/7ba1164d6b62603e3feb67c37e645719.jpg) Date: 2014-05-29 15:30:33Genetic genealogy BioMarin Pharmaceutical Glycogen storage disease type II Acid alpha-glucosidase Lysosomal storage disease Mucopolysaccharidosis Alglucosidase alfa Neuronal ceroid lipofuscinosis Tetrahydrobiopterin Health Rare diseases Medicine | | May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to ImAdd to Reading ListSource URL: www.apjohnventures.comDownload Document from Source Website File Size: 12,70 KBShare Document on Facebook
|